Effectiveness and Tolerability of Eptinezumab - Trial NCT06409845
Access comprehensive clinical trial information for NCT06409845 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Recruiting. The study focuses on Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Eptinezumab 100 or 300 mg ev
Observational
drug
Sponsor & Location
University of Florence
Timeline & Enrollment
N/A
Mar 26, 2024
Apr 01, 2026
Primary Outcome
Changes in migraine frequency after three months of treatment,Percentage of 50% Responders (namely patients who presented a reduction of MMDs / = 50% compared to baseline) after three months of treatment
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and
 tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or
 chronic migraine patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06409845
Non-Device Trial